Last reviewed 2026-04-23 · How we verify

Placebo II (Semaglutide)

Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, reduce appetite, and promote weight loss.

Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, reduce appetite, and promote weight loss. Used for Type 2 diabetes mellitus, Chronic weight management in obese or overweight patients.

At a glance

Mechanism of action

Semaglutide binds to and activates GLP-1 receptors on pancreatic beta cells, enhancing insulin secretion in response to elevated blood glucose. It also acts on the central nervous system to reduce appetite and increase satiety, while slowing gastric emptying. These combined effects lower blood glucose levels and reduce body weight.

Approved indications

• Type 2 diabetes mellitus
• Chronic weight management in obese or overweight patients

Common side effects

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain
• Headache
• Fatigue

Key clinical trials

• A Study of CS060380 Tablets in Patients With MASH and Obesity (PHASE2)
• A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes (PHASE2)
• Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction (PHASE2)
• Semaglutide Therapy for Alcohol Reduction (STAR) (PHASE2)
• The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial (PHASE2)
• A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use (PHASE2)
• UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study (PHASE2)
• Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.